,Total,Monotherapy,Combination,p-value
"SARS-CoV-2 Persistence¹, n (%)",11 (10.6%),3 (9.1%),5 (8.8%),1.000
"All-cause mortality², n (%)",10 (9.6%),2 (6.1%),4 (7.0%),1.000
"SARS-CoV-2-related mortality³, n (%)",5 (4.8%),1 (3.0%),2 (3.5%),1.000
"AE⁴, n (%)",6 (5.8%),1 (3.0%),5 (8.8%),0.409
